Advertisement

Topics

FDA Committee Sees Reduced Cardiovascular Risk with Victoza

09:37 EDT 21 Jun 2017 | PharmPro

Novo Nordisk receives positive 17-2 vote from FDA Advisory Committee that Victoza provides substantial evidence of cardiovascular risk reduction in patients with type 2 diabetes.
Contributed Author: 
Novo Nordisk

Original Article: FDA Committee Sees Reduced Cardiovascular Risk with Victoza

NEXT ARTICLE

More From BioPortfolio on "FDA Committee Sees Reduced Cardiovascular Risk with Victoza"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Cardiology
Cardiology is a specialty of internal medicine.  Cardiac electrophysiology : Study of the electrical properties and conduction diseases of the heart. Echocardiography : The use of ultrasound to study the mechanical function/physics of the h...